California State Teachers Retirement System Trims Stake in iTeos Therapeutics, Inc. (NASDAQ:ITOS)

California State Teachers Retirement System lessened its holdings in iTeos Therapeutics, Inc. (NASDAQ:ITOS) by 5.6% during the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 23,393 shares of the company’s stock after selling 1,387 shares during the period. California State Teachers Retirement System’s holdings in iTeos Therapeutics were worth $319,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. Acadian Asset Management LLC purchased a new stake in shares of iTeos Therapeutics in the 1st quarter valued at about $3,337,000. Jump Financial LLC bought a new position in shares of iTeos Therapeutics in the fourth quarter worth approximately $636,000. Kennedy Capital Management LLC purchased a new stake in iTeos Therapeutics in the first quarter valued at approximately $1,988,000. Federated Hermes Inc. lifted its position in iTeos Therapeutics by 4,648.4% during the fourth quarter. Federated Hermes Inc. now owns 2,944 shares of the company’s stock valued at $32,000 after purchasing an additional 2,882 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its stake in iTeos Therapeutics by 53.3% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,826 shares of the company’s stock worth $97,000 after buying an additional 3,069 shares in the last quarter. Institutional investors own 97.16% of the company’s stock.

Analyst Upgrades and Downgrades

ITOS has been the topic of several research reports. Wedbush restated an “outperform” rating and set a $21.00 price objective on shares of iTeos Therapeutics in a research report on Thursday, August 8th. HC Wainwright increased their target price on iTeos Therapeutics from $44.00 to $46.00 and gave the company a “buy” rating in a research note on Monday, May 13th. JPMorgan Chase & Co. dropped their price target on iTeos Therapeutics from $27.00 to $24.00 and set an “overweight” rating for the company in a research note on Monday, August 12th. Finally, Wells Fargo & Company assumed coverage on iTeos Therapeutics in a report on Tuesday, August 13th. They issued an “overweight” rating and a $31.00 price objective for the company.

iTeos Therapeutics Stock Performance

Shares of iTeos Therapeutics stock opened at $14.94 on Monday. iTeos Therapeutics, Inc. has a 52-week low of $8.20 and a 52-week high of $18.75. The company has a fifty day moving average of $15.72 and a 200-day moving average of $13.75. The stock has a market capitalization of $539.68 million, a price-to-earnings ratio of -3.95 and a beta of 1.40.

iTeos Therapeutics (NASDAQ:ITOS) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.04) by $0.86. The business had revenue of $35.00 million for the quarter, compared to analysts’ expectations of $4.20 million. On average, equities research analysts forecast that iTeos Therapeutics, Inc. will post -4.57 earnings per share for the current fiscal year.

iTeos Therapeutics Company Profile

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.